Journal of diabetes investigation 2017 11 07() doi 10.1111/jdi.12774
Sodium-glucose co-transporter 2 (SGLT2) inhibitors function to increase urinary glucose excretion and improve glycemic control in subjects with type 2 diabetes mellitus. SGLT2 inhibitors as well as diuretics increase urinary volume which leads to the reduction of blood pressure. The aim of this study was to compare the effects of SGLT2 inhibitor and thiazide diuretic on blood pressure, metabolic parameters and body mass composition.
MATERIALS AND METHODS
A total of 31 subjects were enrolled in this study. We switched from thiazide diuretics to an SGLT2 inhibitor ipragliflozin in subjects with type 2 diabetes and hypertension whose blood pressure was controlled with thiazide diuretics. Three months after the switching, we evaluated the effects of such switching on blood pressure, various metabolic parameters and body mass composition.
There was no significant difference in blood pressure from baseline to 3 months later. However, HbA1c, fasting plasma glucose and uric acid were significantly decreased after the switching. Body mass index and visceral fat area were also significantly reduced after the switching. Furthermore, urinary albumin excretion was also significantly decreased after the switching.
Switching from thiazide diuretic to an SGLT2 inhibitor ipragliflozin markedly improved various metabolic parameters and body mass composition without affecting blood pressure in subjects with type 2 diabetes and hypertension This article is protected by copyright. All rights reserved.